AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01297491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
Study NCT01805791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004 1800 mg/day
Description: Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg TID (total dose 1800 mg/day) for 56 days (8 weeks).
Study NCT01822743 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham comparator
Study NCT00525356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Talent Stent-Graft-System
Study NCT01225302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linifanib
Description: Low dose linifanib (once a day)
Study NCT01805791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).
Study NCT01805791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004 2400 mg/day
Description: Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg TID (total dose 2400 mg/day) for 56 days (8 weeks).
Study NCT02942732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: cholecalciferol (Euro-Pharm International, Canada)
Description: All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
Study NCT01225302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linifanib
Description: High dose linifanib (once a day)
Study NCT00000400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human parathyroid hormone [hPTH-(1-34)]
Description: 37 mcg once daily by self-administered sc injection
Study NCT01225302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given on Day 1 of every 21-day cycle
Study NCT01225302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given on Day 1 of every 21-day cycle
Study NCT01392937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: All-in-One Light multipurpose
Description: The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
Study NCT00000400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate
Description: 70 mg/week by oral route
Study NCT00000400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate
Description: 70 mg/week by oral route
Study NCT02177071 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: INFLIXIMAB
Study NCT02177071 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AZATHIOPRINE
Study NCT02177071 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MERCAPTOPURINE
Study NCT01392937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquify care
Description: The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
Study NCT03150212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae CNCM I-3856
Description: 2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
Study NCT02177071 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Study NCT02864654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADRC injection
Description: 10 mL of autologous ADRC suspension will be injected intramuscularly
Study NCT02864654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADRC isolation
Description: ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 10 ml of normal saline.
Study NCT02864654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Study NCT03667456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-rehabilitation by digital support
Description: Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.
Study NCT01015638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and BPO 5% gel
Description: Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
Study NCT01015638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin phosphate and benzoyl peroxide 2.5% gel.
Description: Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
Study NCT03150212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
Study NCT00632359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg daily given for 12 months
Study NCT03956238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Description: Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures
Study NCT01987115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial manipulation
Description: Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
Study NCT01987115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
Study NCT00254072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass
Description: The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.
Study NCT04077359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.
Study NCT04077359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.
Study NCT04075175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S315
Description: Human monoclonal antibody against Diphtheria Toxin
Study NCT04075175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (NaCl)
Description: Placebo 0.9% Sodium Chloride (NaCl)
Study NCT00753519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS
Description: Real iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
Study NCT00753519 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: Sham iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
Study NCT01794702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)
Study NCT01794702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)
Study NCT01794702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)
Study NCT01794702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)~Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion).
Study NCT01735812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IceSense3 system
Description: The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
Study NCT03956238 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol intoxication
Description: Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures
Study NCT04059250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nobio composite
Description: Nobio has developed a bactericidal composite, which does not leak out the bactericidal nano fillers
Study NCT04059250 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: traditional composite
Description: traditional composite which has no bactericidal activities
Study NCT03956238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Objectification
Description: Women assigned to objectifying gazes condition or eye contact control condition
Study NCT03956238 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Objectification
Description: Women assigned to objectifying gazes condition or eye contact control condition
Study NCT00534599 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: oral
Study NCT00534599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine fumarate XR
Description: oral
Study NCT00479752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4 (Oxaliplatin), Cetuximab
Description: Arm A FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².~Arm B FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks.
Study NCT01802047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: milk expression with electric pump
Study NCT04639440 — intervention group
Intervention type: OTHER
Intervention: Adipose tissue
Description: Adipose tissue sampling
Study NCT03007940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coach Site Visit
Description: The coach will conduct a one-day on site visit and will review the walk-through and DDCAT assessment results, and help the change team design an initial change project with Plan-Do-Study-Act (PDSA) cycles. The site visit will use a standardized agenda to ensure NIATx fidelity.
Study NCT03007940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk-through
Description: Walk-Through: Provider change teams will participate in a coach-led webinar that introduces how to conduct a NIATx walk-through from the co-occurring patient perspective and how to write up results using a standard report format. The walk-through will be conducted within two months of the initial coach site visit.
Study NCT03007940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning Sessions
Description: The study includes two one-day coach-led learning sessions. The learning sessions promote peer-to-peer sharing about specific goals and objectives. The agenda is tailored to specific treatment service integration issues. The first coach-led learning session teaches providers how to use NIATx process improvement strategies. Providers share walk-through results and initial change projects. Skill development activities include how to: identify change opportunities, use specific tools (e.g., flowcharting), develop PDSA cycles, effectively use data and learning successful change strategies. At the final session, providers present results, sustainment plans, and identify ways for the group to continue to interact.
Study NCT00947167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: 840 mg, 420 mg, iv
Study NCT00947167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg, PO
Study NCT03007940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching
Description: A NIATx coach leads the active 12 month implementation phase. The coach works with executive directors, change leaders and teams. After the site visit, a coach will hold individual monthly coaching calls (10 hours in total), and participate in group coaching calls (2 hours in total). In the individual calls, the coach and change team review change projects; discuss successes; and identify ideas for future change projects. Group coaching calls involve change leaders from multiple providers. On these calls, change leaders will discuss common change-related issues, progress, and exchange innovative implementation strategies with their peers. These calls provide opportunities for the coach to share new strategies and discuss implementation issues such as the development of a sustain plan.
Study NCT03007940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Business as Usual
Description: Programs in this intervention will continue with their own plans without coaching support to integrate services for individuals with co-occurring substance abuse and mental health disorders. Once the programs in the wait-list control group receive the NIATx Strategy, they will participate in all of the interventions listed above.
Study NCT01171534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaClose fasciotomy closure
Description: The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.
Study NCT01171534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vessel loop
Description: Vessel loops and staples for fasciotomy closure
Study NCT03991975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor.
Study NCT03991975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT02530840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: medical team
Description: Lowering HbA1c by behavioral changes in meetings with the medical team.
Study NCT02530840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peers group
Description: Lowering HbA1c by behavioral changes in meetings with the peers group.
Study NCT02530840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS notification
Description: Lowering HbA1c by behavioral changes in meetings with the SMS notification
Study NCT01693978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, \& Rothbaum, 2007).
Study NCT01693978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, \& Rothbaum, 2007).
Study NCT01693978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher-Based Reinforcement
Description: Those in the PE+CM condition will also be able to earn voucher-based incentives for each therapy session that they attend as scheduled, with a maximum of $480 for full adherence to all sessions. Specifically, participants will earn $30 for attending Session 1, $40 for attending Session 2, $50 for attending Session 3, and $60 for attending Sessions 4 through 9. There will be no payment for Sessions 10 through 12. Because it is very important that participants attend sessions on schedule, voucher values will be reset starting from $30 if participants miss a scheduled session. Vouchers can be exchanged for goods and services in the community (e.g., gift cards to local retailers).
Study NCT03973060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concentric-eccentric muscular work
Description: For muscular contraction, the physiotherapist carried out 12 repetitions with one minute rest between series and series, total working time of 12 minutes.
Study NCT03973060 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic polymorphism
Description: Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine whether the genetic makeup of individuals for the improvement of muscular work in the results of the study.
Study NCT01009619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
Study NCT01009619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
Study NCT00836121 — intervention group
Intervention type: PROCEDURE
Intervention: right thoracotomy
Description: complete surgical resection
Study NCT01766505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candemore tablet
Description: Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.~dosage is depends on the sitting blood pressure.
Study NCT01766505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cozzar tablet
Description: Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure
Study NCT02050204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention was a 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors (Kossek et al., in press). The change process was an integration of two previously evaluated interventions (Hammer et al., 2011; Kelly et al., 2011). A facilitator led 8 hrs of participatory sessions to transition employees from a time-based to a results-based work culture. Supervisors participated in all change activities plus 4hrs of training in supportive supervision. Training in family supportive supervision was implemented with behavioral computer-based training (cTRAIN, NWeta, Lake Oswego, OR) followed by 2 rounds of goal-setting and behavioral self-monitoring using an iPod Touch (Habitrack, OHSU, Portland, OR).
Study NCT03868644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary Counseling and Testing for HIV (VCT)
Description: Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
Study NCT03868644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condoms
Description: Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
Study NCT02909608 — intervention group
Intervention type: OTHER
Intervention: No interventions / observations only
Description: This is an observational study only
Study NCT03084783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
Study NCT01081418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Description: ACT was structured and implemented according to guidelines of the Assertive Community Treatment Association (ACTA). Team members were highly educated psychosis experts consisting of a consultant psychiatrist, a psychiatrist, two psychologists, and a nurse, all of which received training in cognitive behavioral (CBT), dynamic, and/or family psychotherapy. Study participants could use all treatment options within the integrated care program such as psychoeducation groups, social skills training, family groups, motivational addiction therapy, meta-cognitive training etc.
Study NCT02131688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome